Literature DB >> 19160097

NS-398 induces apoptosis in human esophageal cancer cells through inhibition of NF-kappaB downstream regulation of cyclooxygenase-2.

Jun Feng Liu1, Gui Jun Zhu, Glyn G Jamieson, Tie Cheng Wu, Tie Nian Zhu, Bao En Shan, Paul A Drew.   

Abstract

Although non-steroidal anti-inflammatory drugs (NSAIDs) have been demonstrated to have cancer-preventive effects and induce apoptosis of cancer cells, the mechanism of their effects is not clearly known. We studied the mechanism in human esophageal cancer cell line TE13. The esophageal squamous cell carcinoma cell line TE-13 was cultured with NS-398 at different concentrations or for different times. Proliferation and apoptosis were measured by MTT reduction and flow cytometry. Prostaglandin F(1alpha) was determined with radioimmunoassay. Expression of COX-2 mRNA was measured by RT-PCR and COX-2 protein levels with Western blot analysis. Nuclear NF-kappaB and cytoplasmic IkappaB protein levels were determined by electrophoretic mobility shift assay and Western blot, respectively. NS-398 significantly inhibited cell proliferation and induced apoptosis at concentrations of 0.001, 0.01, 1, and 100 micromol/L. NS-398 dose-dependently decreased the levels of COX-2 mRNA, COX-2 protein, nuclear NF-kappaB protein and production of PGF(1alpha) and increased the cytoplasmic IkappaB protein. In conclusion, NS-398 inhibits the proliferation of, and induced apoptosis in, the cultured TE-13 SCC cell line. These changes correlate with a reduction in COX-2 mRNA and protein expression, prostaglandin synthesis, an inhibition of NF-kappaB nuclear translocation, and an increase in cytoplasmic IkappaB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19160097     DOI: 10.1080/07357900801992913

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  5 in total

1.  Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.

Authors:  S Anthony Kahn; Christine M Mullin; Louis-Philippe de Lorimier; Kristine E Burgess; Rebecca E Risbon; Rogers M Fred; Kenneth Drobatz; Craig A Clifford
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

2.  The role of Pea3 group transcription factors in esophageal squamous cell carcinoma.

Authors:  Hiu-Fung Yuen; Cian M McCrudden; Ka-Kui Chan; Yuen-Piu Chan; Michelle Lok-Yee Wong; Kelvin Yuen-Kwong Chan; Ui-Soon Khoo; Simon Law; Gopesh Srivastava; Terence R Lappin; Kwok-Wah Chan; Mohamed El-Tanani
Journal:  Am J Pathol       Date:  2011-05-31       Impact factor: 4.307

3.  The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation.

Authors:  Maria Teresa Valenti; Sandro Giannini; Luca Donatelli; Mirko Zanatta; Francesco Bertoldo; Stefania Sella; Maria Teresa Vilei; Elena Ossi; Giuseppe Realdi; Vincenzo Lo Cascio; Luca Dalle Carbonare
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

4.  Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.

Authors:  Arun George Paul; Neelam Sharma-Walia; Bala Chandran
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

Review 5.  Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.

Authors:  Arun George Paul; Bala Chandran; Neelam Sharma-Walia
Journal:  Transl Res       Date:  2013-04-06       Impact factor: 7.012

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.